Concepedia

Keith Calkins

KC

Statistics

Publications

7

Citations

395

H-Index

7

Active since

2008

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Keith Calkins is an author at Novartis (Switzerland) specializing in oncology, medicine, and molecular oncology.

Publications per year

2008–2024

7

Publications

7

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

Torsten Trowe, Sotiria Boukouvala, Keith Calkins et al. · Clinical Cancer Research · 2008 · 133 citations

, , +14

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Martin Schröder, Martin Renatus, Xiaoyou Liang et al. · Nature Communications · 2024 · 88 citations · Full text

, , +13

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach

Chao Chen, Hugh Zhu, Frédéric Stauffer et al. · ACS Medicinal Chemistry Letters · 2016 · 62 citations · Full text

, , +17

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma

Ellen Weisberg, Basudev Chowdhury, Chengcheng Meng et al. · Blood Cancer Journal · 2022 · 44 citations · Full text

, , +17

New Potent DOT1L Inhibitors for <i>in Vivo</i> Evaluation in Mouse

Frédéric Stauffer, Andreas Weiss, Clemens Scheufler et al. · ACS Medicinal Chemistry Letters · 2019 · 37 citations · Full text

, , +10

1–5 of 7